|
**Overview**: Metanephrines Free Plasma Panel**Introduction**: The Metanephrines Free Plasma Panel is a diagnostic tool designed to screen for pheochromocytoma using plasma samples. In India, pheochromocytoma/paraganglioma is rare (~1-2 per million annually) but underdiagnosed, causing hypertension, palpitations, and catecholamine crisis, with high mortality if undetected. High morbidity from under-testing in rural/low-SES patients with resistant hypertension or paroxysmal symptoms, limited catecholamine labs, delayed alpha-blockade/surgery leading to stroke or cardiac events. Per endocrinology practices aligned with ICMR and Endocrine Society of India guidelines, the test employs spectrophotometry for free metanephrine, normetanephrine, and total metanephrines over 1-2 days with high sensitivity/specificity (>95 percent), valuable as first-line screening superior to urine catecholamines. This diagnostic falls under endocrine screening and targets patients with resistant hypertension, adrenal incidentaloma, or family history, addressing accurate detection to guide imaging (CT/MIBG) or surgery. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise catecholamine metabolite assessment and reducing hypertensive crisis burden. Its plasma-based approach ensures reliable free metanephrine measurement.**Other Names**: Metanephrines P Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.**Historical Milestone**: Plasma free metanephrines standard since 2000s; in India, used in hypertension clinics.**Purpose**: The test assesses 3 parameters including free metanephrine to guide pheochromocytoma screening, detect catecholamine excess, inform imaging/surgery.**Test Parameters**: 1. Free Metanephrine, 2. Free Normetanephrine, 3. Total Metanephrines.**Pretest Condition**: No fasting required; patients should avoid caffeine/tricyclic antidepressants.**Specimen**: 3 mL plasma in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on hypertension, palpitations, family history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected pheochromocytoma including crisis, benefits of screening, and minimal discomfort from sampling.**Procedural Considerations**: The test involves sample processing using spectrophotometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or interfering medications can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Elevated free metanephrines/normetanephrines indicate pheochromocytoma, necessitating specialist input.**Specialist Consultation**: Endocrinologists should be consulted for management.**Additional Supporting Tests**: Plasma catecholamines, CT/MIBG for confirmation.**Test Limitations**: False positives with stress/medications; comprehensive approach required.**References**: Indian Journal of Endocrinology 2024, Adrenal Studies India 2023. |
